Investors & Media

Press Releases

Date Title View
Toggle Summary Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea
Collaboration intended to accelerate development of SAGE-217 in key Asian markets and supports Sage’s mission to bring transformational medicines to patients around the world Collaboration supports Shionogi’s vision of creating a more vigorous society by exploring the potential to provide relief
View HTML
Toggle Summary Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting
Expedited SAGE-217 development plan to support potential NDA submission for MDD and PPD Previously completed placebo-controlled study in MDD considered as pivotal; initiation of one additional Phase 3 pivotal trial anticipated in 2H of 2018 Ongoing study in PPD designated as pivotal; results
View HTML
Toggle Summary Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 39 th Annual
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression
Priority Review status expected to accelerate review period; PDUFA date set for December 19, 2018 If approved, brexanolone IV would be the first and only medication indicated for the treatment of postpartum depression CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Sage Therapeutics (NASDAQ:
View HTML
Toggle Summary Sage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at Bernstein’s 34 th Annual
View HTML
Toggle Summary Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that members of the Sage management team will participate in a
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2018 , the Compensation Committee of Sage’s Board
View HTML
Toggle Summary Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness
New Drug Application for intravenous (IV) formulation of brexanolone as a treatment for postpartum depression submitted to U.S. Food and Drug Administration Significant progress achieved in launch readiness preparations in anticipation of potential 1H 2019 brexanolone IV launch Broad pipeline of
View HTML
Toggle Summary Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 24, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
View HTML